Skip to content

Gyre Therapeutics, Inc. GYRE Gain (loss) on disposal of assets

Discontinued — last reported Q4 '25

Gain (loss) on disposal of assets at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$43.31M
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.87M+131%

Segments

By segment

See full
Gyre Pharmaceuticals-$4K+93.9%

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0.0×
Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Gyre Therapeutics, Inc.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s gain (loss) on disposal of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s gain (loss) on disposal of assets?
Gyre Therapeutics, Inc. (GYRE) reported gain (loss) on disposal of assets of -$2K in Q4 2025.
What does gain (loss) on disposal of assets mean?
Gains or losses recognized on the disposal of businesses, property, equipment, investments, or other assets at prices above or below their carrying value.